OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the stock. OCX has been the topic of several other reports. Needham & Company LLC cut their price objective on OncoCyte from $4.25 to $3.60 and set a […]
More Stories
Byrna Technologies Inc. (NASDAQ:BYRN) Short Interest Up 10.1% in October
Byrna Technologies Inc. (NASDAQ:BYRN – Get Free Report) was the target of a large increase in short interest during the...
Brixmor Property Group (NYSE:BRX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS
Brixmor Property Group (NYSE:BRX – Get Free Report) issued its quarterly earnings results on Monday. The real estate investment trust...
CBAK Energy Technology, Inc. (NASDAQ:CBAT) Short Interest Update
CBAK Energy Technology, Inc. (NASDAQ:CBAT – Get Free Report) saw a large increase in short interest in October. As of...
Astar (ASTR) Hits Self Reported Market Capitalization of $416.87 Million
Astar (ASTR) traded 2% higher against the U.S. dollar during the 24 hour period ending at 21:00 PM Eastern on...
Boston Properties (NYSE:BXP) Releases FY 2024 Earnings Guidance
Boston Properties (NYSE:BXP – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The...
Ripio Credit Network Price Tops $0.0017 on Major Exchanges (RCN)
Ripio Credit Network (RCN) traded 2.6% higher against the US dollar during the 24-hour period ending at 21:00 PM E.T....